Novamab is based in Shanghai, China. It has raised $80M in total funding. Latest round: Series B+.
Novamab funding overview
Novamab is based in Shanghai, China. Novamab has raised $80M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series B+ announced in April 2026. The round record for Novamab runs through 2026; nothing later has been disclosed. Investors on record include Qiming Venture Partners, Jiuyu Investment, Fuho Capital, Nanwan Baiao Fund, Jinyuan Kuntong Equity Investment Management, Zhaode Investment and 6 others. 12 distinct backers are named across the disclosed rounds.
Novamab has raised $80M in total disclosed funding across the rounds on record.
Who has invested in Novamab?
Qiming Venture Partners, Jiuyu Investment, Fuho Capital, Nanwan Baiao Fund, Jinyuan Kuntong Equity Investment Management, Zhaode Investment are named among the investors backing Novamab.
What was the latest Novamab funding round?
The most recent disclosed round is a Series B+, announced in April 2026.
Where is Novamab based?
Novamab is based in Shanghai, China.
When did Novamab last raise?
The last disclosed Novamab round closed in April 2026 at Series B+.
We update the Novamab record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related companies in Shanghai and their backers are listed below.
